Intellia Therapeutics(NTLA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Cash, cash equivalents, and marketable securities decreased to $605.1 million as of December 31, 2025, from $861.7 million as of December 31, 2024 [20] - Collaboration revenue increased to $23 million for Q4 2025, compared to $12.9 million for the same quarter in the previous year [21] - R&D expenses decreased to $88.7 million for Q4 2025 from $116.9 million in the prior year quarter [21] - Net loss for Q4 2025 was $95.8 million, down from $128.9 million for the prior-year quarter [22] Business Line Data and Key Metrics Changes - Enrollment in the MAGNITUDE Phase 3 clinical trial exceeded expectations, with over 650 patients enrolled by October 2025, compared to an initial target of 550 [8] - Enrollment in the HAELO Phase 3 clinical trial was completed with 80 patients in September 2025, ahead of schedule [11] Market Data and Key Metrics Changes - A survey indicated that 99% of patients and caregivers would be at least somewhat likely to take lonvo-z if approved, with nearly two-thirds stating they would be extremely or very likely to take it [12] - 92% of healthcare providers surveyed indicated they could identify a patient to prescribe lonvo-z, representing a significant portion of the treated patient population in the U.S. [13] Company Strategy and Development Direction - The company aims to revolutionize medicine through CRISPR gene editing, focusing on creating one-time treatments with durable efficacy [4][5] - The commercial strategy for lonvo-z includes scaling the field medical team, engaging with physicians and patient advocacy groups, and developing a launch strategy [18][19] - The company anticipates that the commercial success of lonvo-z could fundamentally change its future capital needs [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of lonvo-z and nex-z, citing strong clinical data and patient interest [11][17] - The FDA lifted the clinical hold on MAGNITUDE-2, allowing for continued progress in the clinical trials [9] - Management highlighted the importance of addressing patient safety and regulatory compliance in ongoing studies [32][33] Other Important Information - The company is preparing for a BLA submission for lonvo-z in the second half of 2026, with expectations for a competitive efficacy profile compared to existing therapies [16][45] - The company has established a network of CDMO providers for commercial scale processes, ensuring readiness for the potential launch of lonvo-z [48] Q&A Session Summary Question: Differences in baseline patient characteristics for HAE study - Management confirmed that the patient populations in the Phase 3 trial are largely overlapping with those in Phase 1/2, designed to represent a standard patient population for HAE [24][26] Question: Commercial strategy for HAE - Management indicated that the focus is on educating physicians and scaling the commercial team, with a strong value proposition for patients [30][34] Question: CMC readiness for lonvo-z - Management stated that they are well-prepared for BLA submission and that the material used in the Phase 3 trial is the same as what will be used commercially [44][46] Question: FDA's view on clinical hold differences - Management noted that the FDA views the patient populations for PN and CM as distinct, influencing their decisions regarding clinical holds [61][62] Question: Liver enzyme elevations and immune-mediated reactions - Management acknowledged the immune-mediated nature of liver enzyme elevations and emphasized ongoing monitoring and intervention strategies [57][90]